XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.3
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Common stock, beginning balance (in shares) at Dec. 31, 2023     8,151,000          
Beginning balance at Dec. 31, 2023 $ 47,894 $ 48,148 $ 8 $ 576,971 $ (42) $ (528,081) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (15,375) (15,375)       (15,375)    
Share-based compensation (in shares)     (155,000)          
Share-based compensation 875 875   875        
Net proceeds from issuances of common stock (in shares)     14,000          
Net proceeds from issuances of common stock 32 32   32        
Unrealized gain (loss) on marketable securities 3 3     3      
Foreign currency translation adjustment 7 7     7      
Common stock, ending balance (in shares) at Sep. 30, 2024     8,320,000          
Ending balance at Sep. 30, 2024 33,436 33,690 $ 8 577,878 (32) (543,456) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2024     8,322,000          
Beginning balance at Jun. 30, 2024 37,995 38,249 $ 8 577,552 (77) (538,526) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (4,930) (4,930)       (4,930)    
Share-based compensation (in shares)     (2,000)          
Share-based compensation 326 326   326        
Unrealized gain (loss) on marketable securities 12 12     12      
Foreign currency translation adjustment 33 33     33      
Common stock, ending balance (in shares) at Sep. 30, 2024     8,320,000          
Ending balance at Sep. 30, 2024 $ 33,436 33,690 $ 8 577,878 (32) (543,456) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2024 8,408,844   8,410,000          
Beginning balance at Dec. 31, 2024 $ 29,317 29,571 $ 8 578,418 (81) (548,066) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (13,632) (13,632)       (13,632)    
Share-based compensation (in shares)     (129,000)          
Share-based compensation 748 748   748        
Net proceeds from issuances of common stock (in shares)     214,000          
Net proceeds from issuances of common stock $ 639 639 $ 1 638        
Proceeds from option exercises (in shares) 4,329   4,000          
Proceeds from option exercises $ 8 8   8        
Unrealized gain (loss) on marketable securities 4 4     4      
Foreign currency translation adjustment $ 35 35     35      
Common stock, ending balance (in shares) at Sep. 30, 2025 8,755,948   8,757,000          
Ending balance at Sep. 30, 2025 $ 17,119 17,373 $ 9 579,812 (42) (561,698) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2025     8,627,000          
Beginning balance at Jun. 30, 2025 20,775 21,029 $ 9 579,227 (50) (557,449) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (4,249) (4,249)       (4,249)    
Share-based compensation 232 232   232        
Net proceeds from issuances of common stock (in shares)     130,000          
Net proceeds from issuances of common stock 353 353   353        
Unrealized gain (loss) on marketable securities 1 1     1      
Foreign currency translation adjustment $ 7 7     7      
Common stock, ending balance (in shares) at Sep. 30, 2025 8,755,948   8,757,000          
Ending balance at Sep. 30, 2025 $ 17,119 $ 17,373 $ 9 $ 579,812 $ (42) $ (561,698) $ (708) $ (254)